原發性腎病綜合征患者胰島素抵抗及腎組織ISNR-β、CPR、eNOS的表達

2004 · vol. 23(5) , pp. 298–303 · W2232084155
article OA: closed CC0
View on OpenAlex

Abstract

Objective To investigate insulin resistance (IR), its existent and its possible pathogenesis, the expression of insulin receptor beta (INSR-β), C-peptide receptor (CPR) and endothelial nitric oxide synthase (eNOS) in renal tissue in primary nephrotic syndrome patients. Methods Of all the patients and normal controls, fasting serum glucose (FG), insulin (FISN), C-peptide (FCP) were detected, insulin sensitive index (ISI) was calculated by the formula previously reported. The reported before. The relationship between ISI and blood lipid, ISI and renal function, were investigated. The expression of ISNR-β, CPR and eNOS in renal organism were detected by immunohistochemical staining technique. Results Compared with normal controls, the concentration of FG, FISN, FCP increased significantly (P<0.01 or P<0.05), and ISI decreased significantly (P<0.01) in primary nephrotic syndrome patients. Their ISI correlated negatively with triglyceride (TG)(P<0.05), low density lipoprotein cholesterol (LDL-c)(P<0.05) and blood uric acid (UA)(P<0.01). While, the expressions of INSR-β, CPR and eNOS in renal organism had no statistical differences between patients and controls. Conclusion Primary nepbrotic syndrome patients have insulin resistance and increased concentrations of blood glucose, insulin and C-peptide, the possible reasons for which are blood pressure rise, derangement of blood lipid and UA. While the expression of ISNR-β, CPR and eNOS in renal organism has no significant change in primary nephrotic syndrome patients.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK